Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$90.87 0.64 (0.7%) as of 4:30 Tue 4/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 17.12(B)
Last Volume: 1,235,787 Avg Vol: 1,397,134
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 658,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $62,013,572
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 58
End Date 2024-01-18 2023-10-17 2023-04-18 2022-04-18

   
Records found: 1317
  Page 4 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-06-02 4 AS $57.83 $21,804 D/D (377) 20,190     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-31 4 D $57.96 $17,214 D/D (297) 7,993     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-31 4 D $57.96 $23,937 D/D (413) 20,567     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-30 5 GD $0.00 $0 D/D 180 64,246     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-30 4 GD $23.21 $4,178 D/D 180 56,588     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-05-29 4 D $57.50 $218,040 D/D (3,792) 59,334     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-22 4 AS $56.88 $56,876 I/I (1,000) 46,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-21 4 AS $56.19 $86,817 I/I (1,545) 47,195     -
   Lawlis V Bryan Director   –       •      –    2014-05-16 4 AS $56.87 $96,672 D/D (1,700) 9,700     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-16 4 S $56.86 $105,994 D/D (1,864) 60,950     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-16 4 AS $56.91 $57,136 D/D (1,004) 20,980     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-15 4 D $57.44 $283,294 D/D (4,932) 180,257     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-15 4 D $57.44 $116,948 D/D (2,036) 62,814     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-15 4 D $57.44 $62,954 D/D (1,096) 21,984     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-05-15 4 D $57.44 $71,283 D/D (1,241) 63,126     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-15 4 D $57.44 $11,890 D/D (207) 8,290     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-13 4/A S $58.23 $83,498 D/D (1,434) 63,415     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-13 4 S $58.23 $83,498 D/D (1,434) 64,850     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-13 4 AS $58.18 $27,809 D/D (478) 23,080     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-12 4/A D $59.30 $177,959 D/D (3,001) 64,849     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-12 4 D $57.44 $62,954 D/D (1,096) 56,768     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-12 4 D $59.30 $64,993 D/D (1,096) 57,864     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-12 4 D $59.30 $270,823 D/D (4,567) 185,189     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-12 4 D $59.30 $92,864 D/D (1,566) 66,284     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-12 4 D $59.30 $16,723 D/D (282) 8,497     -
  1317 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us